Dr Paul Huang’s team aims to understand how networks of signalling-proteins control tumour progression and drug resistance in cancer.
Dr Paul Huang uses systems biology and molecular pathology to study drug resistance in sarcomas and lung cancer. He trained at Imperial College London and Massachusetts Institute of Technology, and was awarded a Sir Henry Wellcome Fellowship in 2009 and a Cancer Research UK Career Establishment Award in 2015.
I am currently working on utilising radiogenomics to understand heterogeneity and therapy response in soft tissue sarcoma, and whether combining imaging and molecular data can improve patient outcomes.
I am working to understand how drug resistance in soft tissue sarcomas develops, by using mass spectrometry to generate proteomic profiles in tumour specimens.
I am a first year PhD student and my work will be focussed on analysing post translational modifications, particularly phosphoproteomics by mass spectrometry in soft tissue sarcomas.
I am an administrative assistant within the Division of Molecular Pathology. I have a keen interest in the world of oncology and am enthusiastic about supporting those who are making a real difference in their work.
I am currently a PhD student researching the mechanisms of resistance in soft tissue sarcoma to the tyrosine kinase inhibitors.
I am working to validate a molecular signature developed in the lab, which identifies patient subgroups with distinct therapy outcomes, in advanced soft tissue sarcoma.
I joined the ICR in 2016 and am researching the functional distinctions between different EGFR mutations that are seen across all cancer types.
I began my postdoctoral career at the ICR in 2015. Initially working for the Signal Transduction Team (Barbara Tanos) and subsequently joining the Molecular and Systems Oncology Team in 2018. My current research is focused on understanding sub-clonal interactions and tumour heterogeneity driving EGFR inhibitor resistance in lung cancer.
I am a PhD student and my research focuses on understanding kinase inhibitor resistance mechanisms in soft tissue sarcomas and lung cancers. To do this I am also working to develop better 2D and 3D sarcoma and lung models which are more similar to tumours in the body.
I am interested in the proteomics of the extracellular matrix during breast cancer progression and in SWATH mass spectrometry development for clinical proteomics.
I work at the ICR as a PhD student, where I work to investigate the molecular characteristics and functional mechanisms of oncogenic FGFR3 mutations in cancer to improve targeted therapies.
I am a Postdoctoral training fellow working on the evolution of acquired resistance to targeted EGFR therapy in non-small-cell lung cancer.
I am a 1st year PhD student and I’ll be using proteomics to better understand mechanisms of chemoresistance in soft tissue sarcoma (STS), characterising extracellular proteins and associated proteins (matrisome) to do this.
Previous to working in the Huang lab, I worked for the GI unit as a Specimen Co-ordinator. Now, my role as Tissue Manager involves collecting and banking tissue samples of rare sarcoma subtypes to facilitate current and future research projects for the Huang lab.
I have recently, successfully completed a PhD in the Huang Lab at the ICR and now continue my work as a postdoctoral training fellow to identify novel strategies to overcome de novo resistance to EGFR inhibitors in lung cancer.
I left the major trauma centre in Coventry to join the ICR in 2018 as a clinical PhD fellow. My research is focused on identifying biomarkers for response to tyrosine kinase inhibitors, in soft tissue sarcomas, through characterisation of the immune microenvironment.